7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Uremia D014511 33 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Neoplasms, Experimental D009374 10 associated lipids
Hypercalcemia D006934 13 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Lung Neoplasms D008175 171 associated lipids
Wounds and Injuries D014947 20 associated lipids
Pancreatic Neoplasms D010190 77 associated lipids
Inflammation D007249 119 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Diabetic Nephropathies D003928 39 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Body Weight D001835 333 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Han X et al. Expression of receptor activator of nuclear factor-kappaB ligand by B cells in response to oral bacteria. 2009 Oral Microbiol. Immunol. pmid:19416447
Yildirim S et al. Human cytomegalovirus, Epstein-Barr virus and bone resorption-inducing cytokines in periapical lesions of deciduous teeth. 2006 Oral Microbiol. Immunol. pmid:16476020
Nakamura H et al. Lack of Toll-like receptor 4 decreases lipopolysaccharide-induced bone resorption in C3H/HeJ mice in vivo. 2008 Oral Microbiol. Immunol. pmid:18402604
Lu HK et al. An acute injection of Porphyromonas gingivalis lipopolysaccharide modulates the OPG/RANKL system and interleukin-6 in an ovariectomized mouse model. 2008 Oral Microbiol. Immunol. pmid:18402608
Katagiri T and Takahashi N Regulatory mechanisms of osteoblast and osteoclast differentiation. 2002 Oral Dis pmid:12108759
Yamamoto T et al. Mechanical stress induces expression of cytokines in human periodontal ligament cells. 2006 Oral Dis pmid:16476039
Yamamoto K et al. Effects of mechanical stress on cytokine production in mandible-derived osteoblasts. 2011 Oral Dis pmid:21771211
Park OJ et al. The association of osteoprotegerin gene polymorphisms with periodontitis. 2008 Oral Dis pmid:18938269
Nakano M et al. Inhibitory effect of titanium particles on osteoclast formation generated by treatment of mouse bone marrow cells with PGE2. 2003 Oral Dis pmid:12657033
Pitari MR et al. Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts. 2015 Oncotarget pmid:26160841
Schieferdecker A et al. Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL. 2014 Oncotarget pmid:25138051
Fioramonti M et al. Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions. 2017 Oncotarget pmid:28223547
Murthy RK et al. Bone biology and the role of the RANK ligand pathway. 2009 Oncology (Williston Park, N.Y.) pmid:20128323
Shan Y et al. p38 MAPK plays a distinct role in sulforaphane-induced up-regulation of ARE-dependent enzymes and down-regulation of COX-2 in human bladder cancer cells. 2010 Oncol. Rep. pmid:20204301
D'Amico L et al. Bone metastases in gastric cancer follow a RANKL-independent mechanism. 2013 Oncol. Rep. pmid:23404437
Lv Z et al. Bone morphogenetic protein 9 regulates tumor growth of osteosarcoma cells through the Wnt/β-catenin pathway. 2014 Oncol. Rep. pmid:24337584
Martinetti A et al. Short-term effects of pamidronate on bone turnover: can bone markers be considered predictive of the analgesic response? 2007 Oncol. Rep. pmid:17487415
Holecki M et al. The influence of weight loss on serum osteoprotegerin concentration in obese perimenopausal women. 2007 Obesity (Silver Spring) pmid:17712108
Son E et al. Induction of alkaline phosphatase activity by L-ascorbic acid in human osteoblastic cells: a potential role for CK2 and Ikaros. 2007 Nutrition pmid:17664058
Pellegrini GG et al. Avenanthramides Prevent Osteoblast and Osteocyte Apoptosis and Induce Osteoclast Apoptosis in Vitro in an Nrf2-Independent Manner. 2016 Nutrients pmid:27409635
Martin-Bautista E et al. Improvement of bone formation biomarkers after 1-year consumption with milk fortified with eicosapentaenoic acid, docosahexaenoic acid, oleic acid, and selected vitamins. 2010 Nutr Res pmid:20579524
Marini H et al. Efficacy of genistein aglycone on some cardiovascular risk factors and homocysteine levels: A follow-up study. 2010 Nutr Metab Cardiovasc Dis pmid:19631515
Huang JW et al. Osteoprotegerin, inflammation and dyslipidemia are associated with abdominal aortic calcification in non-diabetic patients on peritoneal dialysis. 2014 Nutr Metab Cardiovasc Dis pmid:24361071
Mori T et al. RNA aptamers selected against the receptor activator of NF-kappaB acquire general affinity to proteins of the tumor necrosis factor receptor family. 2004 Nucleic Acids Res. pmid:15562003
Azuma Y [Animal models of osteoporosis and development of anti-osteoporotic agents]. 2007 Nippon Yakurigaku Zasshi pmid:17878615
Wada T [RANKL inhibition in bone metastases]. 2013 Nippon Yakurigaku Zasshi pmid:23302944
Kawaguchi H [Approach for therapeutic targets of osteoarthritis]. 2011 Nippon Yakurigaku Zasshi pmid:21747205
Inoue D and Matsumoto T [Recent advances in basic research of bone metabolism]. 2002 Nippon Rinsho pmid:11979916
Suzuki Y et al. [Bone destruction and bone loss in rheumatoid arthritis--mechanism, prevention and treatment]. 2002 Nippon Rinsho pmid:11979937
Suda T and Miyaura C [Recent advance in basic research for osteoporosis]. 2004 Nippon Rinsho pmid:15035090
Matsumoto T [Recent advances in the regulation of bone remodeling]. 2004 Nippon Rinsho pmid:15035093
Okumura S et al. [Regulatory mechanism of osteoclast differentiation and function]. 2004 Nippon Rinsho pmid:15035103
Udagawa N et al. [Possible role of RANKL in bone resorption]. 2004 Nippon Rinsho pmid:15035104
Okazaki T [PTH-related protein producing tumor]. 2006 Nippon Rinsho pmid:17022555
Inoue D [OPG(osteoprotegerin)/OCIF(osteoclastogenesis inhibitory factor)]. 2004 Nippon Rinsho pmid:15035105
Suzuki Y [Stimulator of bone resorption interleukin-1, interleukin-6 and gp-130 cytokine family]. 2004 Nippon Rinsho pmid:15035106
Miyaura C [LPS]. 2004 Nippon Rinsho pmid:15035108
Tanaka Y [Adhesion molecules in the context with bone remodeling and osteoporosis]. 2004 Nippon Rinsho pmid:15035110
Tomoyasu A and Higashio K [Osteoclastogenesis inhibitory factor/osteoprotegerin(OCIF/OPG)]. 2004 Nippon Rinsho pmid:15035190
Sohen S [Glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis and collagen diseases]. 2004 Nippon Rinsho pmid:15035207
Tanaka Y [Secondary osteoporosis due to systemic autoimmune diseases and rheumatic diseases]. 2004 Nippon Rinsho pmid:15035208
Fukunaga J and Sugahara T [Osteoporosis induced by immunosuppressant]. 2004 Nippon Rinsho pmid:15035219
Juji T and Tanaka S [Novel therapeutic approach to bone metabolic disorders using RANKL vaccination]. 2004 Nippon Rinsho pmid:15035230
Chaki O [Osteoporosis]. 2006 Nippon Rinsho pmid:16689336
Takahashi N et al. [Osteoprotegerin (OPG)]. 2010 Nippon Rinsho pmid:20960766
Yasuda H [OPG, anti-rANKL antibody]. 2005 Nippon Rinsho pmid:16164225
Takahashi N et al. [Osteoprotegerin (OPG)]. 2005 Nippon Rinsho pmid:16149650
Takayanagi H [Cross-talk between immune and skeletal systems]. 2002 Nippon Rinsho pmid:12510352
Nakamura M et al. [Osteoclastogenesis and bone resorption]. 2009 Nippon Rinsho pmid:19432105
Masuda H and Tanaka S [Drugs under development for osteoporosis ]. 2009 Nippon Rinsho pmid:19432120

Table of Content